Cargando…

Liver X Receptor Inverse Agonist SR9243 Suppresses Nonalcoholic Steatohepatitis Intrahepatic Inflammation and Fibrosis

Abnormal metabolism of cholesterol may be a contributing factor in nonalcoholic steatohepatitis (NASH) pathogenesis. Accumulating evidence has shown that liver X receptor (LXR) is closely related to intrahepatic inflammation and fibrosis. In this study, we evaluated the effects of a novel liver-spec...

Descripción completa

Detalles Bibliográficos
Autores principales:	Huang, Peng, Kaluba, Benson, Jiang, Xiao-lin, Chang, Shi, Tang, Xiao-feng, Mao, Lin-feng, Zhang, Zhi-peng, Huang, Fei-zhou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2018
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5835296/ https://www.ncbi.nlm.nih.gov/pubmed/29670908 http://dx.doi.org/10.1155/2018/8071093

Ejemplares similares

The LXR inverse agonist SR9238 suppresses fibrosis in a model of non-alcoholic steatohepatitis
por: Griffett, Kristine, et al.
Publicado: (2015)

Hyperuricemia Inversely Correlates with Disease Severity in Taiwanese Nonalcoholic Steatohepatitis Patients
por: Huang, Jee-Fu, et al.
Publicado: (2015)

Differential Intrahepatic Phospholipid Zonation in Simple Steatosis and Nonalcoholic Steatohepatitis
por: Wattacheril, Julia, et al.
Publicado: (2013)

Recombinant SFRP5 protein significantly alleviated intrahepatic inflammation of nonalcoholic steatohepatitis
por: Chen, Lili, et al.
Publicado: (2017)

Overexpression of Hepcidin Alleviates Steatohepatitis and Fibrosis in a Diet-induced Nonalcoholic Steatohepatitis
por: Chen, Hui, et al.
Publicado: (2022)

Polydatin attenuates diet-induced nonalcoholic steatohepatitis and fibrosis in mice
por: Li, Rui, et al.
Publicado: (2018)

Intragastric Balloons: An Emerging Therapy for Nonalcoholic Steatohepatitis and Fibrosis?
por: Jirapinyo, Pichamol, et al.
Publicado: (2019)

Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
por: Sayiner, Mehmet, et al.
Publicado: (2018)

Isorhamnetin Alleviates Steatosis and Fibrosis in Mice with Nonalcoholic Steatohepatitis
por: Ganbold, Munkhzul, et al.
Publicado: (2019)

A simple method for inducing nonalcoholic steatohepatitis with fibrosis
por: Yahaghi, Leyla, et al.
Publicado: (2019)

Circulating Citrate Is Associated with Liver Fibrosis in Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
por: Amjad, Waseem, et al.
Publicado: (2023)

Therapeutic effect and autophagy regulation of myriocin in nonalcoholic steatohepatitis
por: Yang, Rui-Xu, et al.
Publicado: (2019)

Value of controlled attenuation parameter in fibrosis prediction in nonalcoholic steatohepatitis
por: Lee, Jung Il, et al.
Publicado: (2019)

Treating nonalcoholic steatohepatitis with antidiabetic drugs: Will GLP-1 agonists end the struggle?
por: Kalogirou, Maria, et al.
Publicado: (2018)

Ferroptosis plays a novel role in nonalcoholic steatohepatitis pathogenesis
por: Xiong, Fei, et al.
Publicado: (2022)

AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
por: Xu, Hongjiao, et al.
Publicado: (2020)

Necroptosis in Nonalcoholic Steatohepatitis
por: Gautheron, Jérémie, et al.
Publicado: (2015)

Sugar-Sweetened Beverages and Artificially Sweetened Beverages Consumption and the Risk of Nonalcoholic Fatty Liver (NAFLD) and Nonalcoholic Steatohepatitis (NASH)
por: Tseng, Tung-Sung, et al.
Publicado: (2023)

Combination of an ACLY inhibitor with a GLP-1R agonist exerts additive benefits on nonalcoholic steatohepatitis and hepatic fibrosis in mice
por: Desjardins, Eric M., et al.
Publicado: (2023)

Exercise changes the intrahepatic immune cell profile and inhibits the progression of nonalcoholic steatohepatitis in a mouse model
por: Tsutsui, Yuriko, et al.
Publicado: (2023)

Modulating sphingosine 1-phosphate receptor signaling skews intrahepatic leukocytes and attenuates murine nonalcoholic steatohepatitis
por: Liao, Chieh-Yu, et al.
Publicado: (2023)

Human Nonalcoholic Steatohepatitis on a Chip
por: Freag, May S., et al.
Publicado: (2020)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis
por: Mazo, Daniel FC, et al.
Publicado: (2013)

Resveratrol ameliorates fibrosis and inflammation in a mouse model of nonalcoholic steatohepatitis
por: Kessoku, Takaomi, et al.
Publicado: (2016)

Recent Insight into the Role of Fibrosis in Nonalcoholic Steatohepatitis-Related Hepatocellular Carcinoma
por: Sircana, Antonio, et al.
Publicado: (2019)

Plasma eicosanoids as noninvasive biomarkers of liver fibrosis in patients with nonalcoholic steatohepatitis
por: Caussy, Cyrielle, et al.
Publicado: (2020)

Prevalence and risk factors of nonalcoholic steatohepatitis with significant fibrosis in people with HIV
por: Michel, Maurice, et al.
Publicado: (2022)

Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in rat model of nonalcoholic steatohepatitis
por: Hu, Ying-Bin, et al.
Publicado: (2018)

Potential Hepatic Lipid Markers Associated with Nonalcoholic Steatohepatitis and Fibrosis in Morbid Obesity Patients
por: Wu, Hua-Chien, et al.
Publicado: (2023)

A novel diet‐induced murine model of steatohepatitis with fibrosis for screening and evaluation of drug candidates for nonalcoholic steatohepatitis
por: Ejima, Chieko, et al.
Publicado: (2016)

Apoptosis and diagnosis of nonalcoholic steatohepatitis
por: Kim, Chang Wook, et al.
Publicado: (2011)

Antioxidant Therapy in Nonalcoholic Steatohepatitis
por: Al-Busafi, Said A., et al.
Publicado: (2012)

The Immune Landscape in Nonalcoholic Steatohepatitis
por: Narayanan, Sowmya, et al.
Publicado: (2016)

Betel Chewing and Nonalcoholic Steatohepatitis
por: Bleibel, Wissam, et al.
Publicado: (2018)

The metabolic basis of nonalcoholic steatohepatitis
por: Chakravarthy, Manu V., et al.
Publicado: (2020)

Pathogenesis of Nonalcoholic Steatohepatitis: An Overview
por: Parthasarathy, Gopanandan, et al.
Publicado: (2020)

Insulinoma in Patient With Nonalcoholic Steatohepatitis
por: Cain, Daniel, et al.
Publicado: (2023)

Challenges and opportunities in nonalcoholic steatohepatitis
por: Wang, Xiaobo
Publicado: (2022)

Author Correction: AdipoR1/AdipoR2 dual agonist recovers nonalcoholic steatohepatitis and related fibrosis via endoplasmic reticulum-mitochondria axis
por: Xu, Hongjiao, et al.
Publicado: (2021)

S-nitroso-N-acetylcysteine attenuates liver fibrosis in experimental nonalcoholic steatohepatitis [Corrigendum]
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_5rhd4ve8lvgg0qd6qv0e9297qe